Celastrol increases glucocerebrosidase activity in Gaucher disease by modulating molecular chaperones

Novel HIF2A mutations disrupt oxygen sensing, leading to polycythemia, paragangliomas, and somatostatinomas

(2013) C. Yang et al.   BLOOD

Histone deacetylase inhibitors increase glucocerebrosidase activity in Gaucher disease by modulation of molecular chaperones

(2013) C. Yang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Histone deacetylase inhibitors are neuroprotective and preserve NGF-mediated cell survival following traumatic brain injury

(2013) J. Lu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Proteostasis Modulators Prolong Missense VHL Protein Activity and Halt Tumor Progression

(2013) Chunzhang Yang et al.   Cell Reports

Gaucher disease paradigm: From ERAD to comorbidity

(2012) Inna Bendikov-Bar et al.   HUMAN MUTATION

A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors

(2012) Akira Fukutomi et al.   INVESTIGATIONAL NEW DRUGS

An innovative approach to the treatment of Gaucher disease and possibly other metabolic disorders of the brain

(2012) Roscoe O. Brady et al.   JOURNAL OF INHERITED METABOLIC DISEASE

Development of B Cells and Erythrocytes Is Specifically Impaired by the Drug Celastrol in Mice

(2012) Sophie Kusy et al.   PLoS One

Hsp90 Inhibitors Are Efficacious against Kaposi Sarcoma by Enhancing the Degradation of the Essential Viral Gene LANA, of the Viral Co-Receptor EphA2 as well as Other Client Proteins

(2012) Wuguo Chen et al.   PLoS Pathogens

BAG3 Protein Is Overexpressed in Human Glioblastoma and Is a Potential Target for Therapy

(2011) Michelina Festa et al.   AMERICAN JOURNAL OF PATHOLOGY

Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90

(2011) Kamalika Moulick et al.   Nature Chemical Biology

Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease

(2011) J. Lu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Characterization of the ERAD process of the L444P mutant glucocerebrosidase variant

(2010) Inna Bendikov-Bar et al.   BLOOD CELLS MOLECULES AND DISEASES

Heat Shock Protein 90 Inhibition Depletes LATS1 and LATS2, Two Regulators of the Mammalian Hippo Tumor Suppressor Pathway

(2010) C. J. Huntoon et al.   CANCER RESEARCH

Celastrol can inhibit proteasome activity and upregulate the expression of heat shock protein genes, hsp30 and hsp70, in Xenopus laevis A6 cells

(2010) Shantel E. Walcott et al.   COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY A-MOLECULAR & INTEGRATIVE PHYSIOLOGY

Chemical and/or biological therapeutic strategies to ameliorate protein misfolding diseases

(2010) Derrick Sek Tong Ong et al.   CURRENT OPINION IN CELL BIOLOGY

Toxic effects of celastrol on embryonic development of zebrafish (Danio rerio)

(2010) Sifeng Wang et al.   DRUG AND CHEMICAL TOXICOLOGY

HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans

(2010) Sachie Marubayashi et al.   JOURNAL OF CLINICAL INVESTIGATION

The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1

(2010) Saad Z Usmani et al.   Journal of Hematology & Oncology

A DNAJB Chaperone Subfamily with HDAC-Dependent Activities Suppresses Toxic Protein Aggregation

(2010) Jurre Hageman et al.   MOLECULAR CELL

IKK  protein is a target of BAG3 regulatory activity in human tumor growth

(2010) M. Ammirante et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Decreased glucocerebrosidase activity in Gaucher disease parallels quantitative enzyme loss due to abnormal interaction with TCP1 and c-Cbl

(2010) J. Lu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Protein quality control during aging involves recruitment of the macroautophagy pathway by BAG3

(2009) Martin Gamerdinger et al.   EMBO JOURNAL

Targeting heat shock protein 90 with non-quinone inhibitors: A novel chemotherapeutic approach in human hepatocellular carcinoma

(2009) Marco Breinig et al.   HEPATOLOGY

Characterization of Celastrol to Inhibit Hsp90 and Cdc37 Interaction

(2009) Tao Zhang et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6–dependent B cell lymphomas

(2009) Leandro C Cerchietti et al.   NATURE MEDICINE

Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models

(2009) E. Caldas-Lopes et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Structural and Functional Diversities between Members of the Human HSPB, HSPH, HSPA, and DNAJ Chaperone Families†

(2008) Michel J. Vos et al.   BIOCHEMISTRY

Chemical and Biological Approaches Synergize to Ameliorate Protein-Folding Diseases

(2008) Ting-Wei Mu et al.   CELL

Activation of Heat Shock and Antioxidant Responses by the Natural Product Celastrol: Transcriptional Signatures of a Thiol-targeted Molecule

(2008) Amy Trott et al.   MOLECULAR BIOLOGY OF THE CELL

A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells

(2008) T. Zhang et al.   MOLECULAR CANCER THERAPEUTICS